Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(3 years from now) | |
US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(4 years from now) | |
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(6 years from now) |
Triumeq Pd is owned by Viiv Hlthcare.
Triumeq Pd contains Abacavir Sulfate; Dolutegravir Sodium; Lamivudine.
Triumeq Pd has a total of 4 drug patents out of which 0 drug patents have expired.
Triumeq Pd was authorised for market use on 30 March, 2022.
Triumeq Pd is available in tablet, for suspension;oral dosage forms.
The generics of Triumeq Pd are possible to be released after 08 June, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jun 15, 2026 |
Pediatric Exclusivity (PED) | Dec 15, 2026 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 30 March, 2022
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL